Search
for
Sort by
Research 421–450 of 1000+
- Safety of dermatologic medications in pregnancy and lactation
- Frontal Fibrosing Alopecia: An Update on Pathogenesis, Diagnosis, and Treatment
- Molecular targeted therapies for cancer: Sorafenib mono�therapy and its combination with other therapies (Review)
- Immune cell regulation of the hair cycle
- The Current Status of the Pharmaceutical Potential of Juniperus L. Metabolites
- Predominant expression of 5 alpha-reductase type 1 in pubic skin from normal subjects and hirsute patients.
- Endocrine treatment of benign prostatichypertrophy: Current concepts
- Enhancement of In Vitro Hair Shaft Elongation in Follicles Stored in Buffers That Prevent Follicle Cell Apoptosis
- Severe skin toxicity during whole-brain radiotherapy, targeted therapy, and additional drug intake including St. John’s wort skin oil
- The role of Wnt and Shh signaling systems in noggin-induced tumorigenesis
- Hutchinson-Gilford syndrome: History, causes, phenotype and research advances
- Cutaneous Lupus Erythematosus
- Enhancement of In Vitro Hair Shaft Elongation in Follicles Stored in Buffers That Prevent Follicle Cell Apoptosis
- Stem Cell Competition for Niche Occupancy: Emerging Themes and Mechanisms
- A comparative analysis of immune privilege in pregnancy and cancer in the context of checkpoint blockade immunotherapy
- Madarosis, milphosis, eyelash trichomegaly, and dermatochalasis
- Mesenchymal–epithelial interactions during hair follicle morphogenesis and cycling
- JAK 1-3 inhibitors and TYK-2 inhibitors in dermatology: Practical pearls for the primary care physician
- Multicentric parallel phase II trial of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organization for Research and Treatment of Cancer (EORTC) Network Of Core Institutes (NOCI)
- JAK Inhibitors for Treatment of Alopecia Areata
- [JAK INHIBITORS FOR THE TREATMENT OF ALOPECIA AREATA].
- First-in-human phase 1 study of ETC-159 an oral PORCN inhbitor in patients with advanced solid tumours.
- The development of oral hairy leukoplakia during JAK inhibitor baricitinib therapy
- The 5α-reductase inhibitor finasteride reduces opioid self-administration in animal models of opioid use disorder
- LB1056 Phase 1b: Translational evaluation of VYN201, a pan-BD BET inhibitor, for the treatment of non-segmental vitiligo
- Emerging Topical and Systemic JAK Inhibitors in Dermatology
- Abstract 1677: Epithelial hyperplasia induced by a selective B-Raf inhibitor, WYE-130600
- Tyrosine Kinase Inhibitors against Cancer: Their Safety in 216 Moroccan Patients
- Targeted Overexpression of the Angiogenesis Inhibitor Thrombospondin-1 in the Epidermis of Transgenic Mice Prevents Ultraviolet-B-Induced Angiogenesis and Cutaneous Photo-Damage
- 153 Effectiveness of OR-101, a next generation highly selective JAK3 inhibitor, in a humanized murine model of alopecia areata